Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.17 - $1.92 $833 - $1,367
712 Added 0.09%
823,111 $1.31 Million
Q4 2023

Feb 14, 2024

BUY
$0.6 - $1.31 $16,725 - $36,517
27,876 Added 3.51%
822,399 $707,000
Q3 2023

Nov 14, 2023

SELL
$1.05 - $3.37 $65,145 - $209,084
-62,043 Reduced 7.24%
794,523 $850,000
Q2 2023

Aug 14, 2023

BUY
$2.44 - $4.53 $286,002 - $530,979
117,214 Added 15.85%
856,566 $2.22 Million
Q1 2023

May 15, 2023

BUY
$3.72 - $5.4 $129,459 - $187,925
34,801 Added 4.94%
739,352 $3.02 Million
Q4 2022

Feb 14, 2023

SELL
$3.41 - $12.93 $514,991 - $1.95 Million
-151,024 Reduced 17.65%
704,551 $3.54 Million
Q3 2022

Nov 15, 2022

BUY
$12.59 - $17.67 $1.07 Million - $1.5 Million
85,133 Added 11.05%
855,575 $11.2 Million
Q2 2022

Aug 15, 2022

BUY
$10.58 - $17.5 $835,142 - $1.38 Million
78,936 Added 11.42%
770,442 $9.88 Million
Q1 2022

May 16, 2022

BUY
$13.81 - $18.6 $222,700 - $299,943
16,126 Added 2.39%
691,506 $10.5 Million
Q4 2021

Feb 14, 2022

BUY
$17.26 - $22.02 $935,785 - $1.19 Million
54,217 Added 8.73%
675,380 $12 Million
Q3 2021

Nov 15, 2021

BUY
$20.15 - $26.19 $534,881 - $695,213
26,545 Added 4.46%
621,163 $13.1 Million
Q2 2021

Aug 16, 2021

BUY
$15.06 - $30.03 $1.61 Million - $3.21 Million
106,936 Added 21.93%
594,618 $11.7 Million
Q1 2021

May 17, 2021

BUY
$24.99 - $31.93 $561,750 - $717,754
22,479 Added 4.83%
487,682 $14.2 Million
Q4 2020

Feb 16, 2021

BUY
$16.21 - $31.44 $380,983 - $738,934
23,503 Added 5.32%
465,203 $14.1 Million
Q3 2020

Nov 10, 2020

SELL
$15.59 - $19.97 $357,416 - $457,832
-22,926 Reduced 4.93%
441,700 $7.03 Million
Q2 2020

Aug 14, 2020

BUY
$11.97 - $23.47 $66,720 - $130,821
5,574 Added 1.21%
464,626 $9.17 Million
Q1 2020

May 11, 2020

BUY
$10.0 - $19.51 $4.59 Million - $8.96 Million
459,052 New
459,052 $5.66 Million

Others Institutions Holding NGM

About NGM BIOPHARMACEUTICALS INC


  • Ticker NGM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,365,904
  • Description
  • NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...
More about NGM
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.